Physician profile
Eric B Jacoby
NPI 1437158441
$6,810.98
in general payments reported to CMS, 2019-2025
25 companies · $2,191 in 2025
The $2,191 reported for 2025 was more than what 95% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $398 · 2021: $430 · 2022: $295 · 2023: $936 · 2024: $1,955 · 2025: $2,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,400 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500 · Food and Beverage: $1,082 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,400.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
| Food and Beverage | $1,082.49 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $2,400.00 | 2024-2025 | |
| Intuitive Surgical, INC. | $1,500.00 | 2023-2024 | Da Vinci Surgical System |
| Abbvie INC. | $580.50 | 2019-2025 | |
| Astellas Pharma US INC | $448.05 | 2023-2025 | Veozah |
| Becton, Dickinson and Company | $326.67 | 2019 | |
| Millicent US INC | $288.63 | 2020-2025 | Intrarosa, Femring, Femlyv |
| Therapeuticsmd, INC. | $286.18 | 2019-2022 | |
| Minerva Surgical, INC | $253.66 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $185.44 | 2021-2024 | |
| Coopersurgical, INC. | $134.02 | 2020-2025 | Ally II Ups |
| Exeltis, USA INC. | $84.27 | 2023-2025 | Slynd |
| Currax Pharmaceuticals LLC | $77.33 | 2020-2022 | |
| Organon LLC | $40.02 | 2024 | |
| Novo Nordisk INC | $23.33 | 2019 | |
| Pfizer INC. | $23.17 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $20.24 | 2021 | |
| Meditrina | $19.80 | 2025 | |
| Sumitomo Pharma America, INC. | $18.75 | 2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $18.71 | 2019 | |
| Hologic Sales and Service, LLC | $15.53 | 2019 | |
| Galderma Laboratories, L.P. | $15.16 | 2021 | |
| Medicem INC. | $13.78 | 2021 | |
| Duchesnay USA Incorporated | $13.01 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.92 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Jacoby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.